KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Astrazeneca (AZN) over the last 15 years, with Q4 2025 value amounting to -$1.5 billion.

  • Astrazeneca's Net Cash Flow fell 17200.97% to -$1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.4 billion, marking a year-over-year increase of 1104.36%. This contributed to the annual value of $4.4 billion for FY2025, which is 1104.36% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Net Cash Flow is -$1.5 billion, which was down 17200.97% from $2.2 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Net Cash Flow registered a high of $8.6 billion during Q2 2021, and its lowest value of -$8.1 billion during Q3 2021.
  • Its 5-year average for Net Cash Flow is $643.6 million, with a median of $307.5 million in 2021.
  • Per our database at Business Quant, Astrazeneca's Net Cash Flow plummeted by 19169.68% in 2022 and then soared by 217357.14% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's Net Cash Flow stood at $198.0 million in 2021, then crashed by 37.88% to $123.0 million in 2022, then surged by 502.44% to $741.0 million in 2023, then surged by 178.68% to $2.1 billion in 2024, then plummeted by 172.01% to -$1.5 billion in 2025.
  • Its Net Cash Flow was -$1.5 billion in Q4 2025, compared to $2.2 billion in Q3 2025 and $3.2 billion in Q2 2025.